Very Low Doses of a CB1 Blocker Correct Key Features of Fragile X Syndrome in Mice
Doses of the CB1 receptor blocker rimonabant 30 to 300 times lower than those causing psychiatric side effects in humans normalized brain signaling and cognitive deficits in a mouse model of Fragile X syndrome.
Quick Facts
What This Study Found
Fragile X syndrome is the most common genetic cause of intellectual disability. Previous research from this group showed that blocking CB1 cannabinoid receptors with rimonabant corrected multiple features of the disease in mice. However, rimonabant was pulled from the market as an obesity drug due to psychiatric side effects at the doses used for weight loss.
This study asked whether much lower doses could still work. The answer was yes. Doses of rimonabant as low as 0.01 mg/kg normalized the memory deficit in Fragile X mice, and 0.1 mg/kg corrected abnormal brain signaling (mGluR-dependent long-term depression). These doses are 30 to 300 times lower than those needed for weight loss and presumably for causing side effects.
Additionally, a "neutral" CB1 antagonist called NESS0327, which blocks the receptor without the inverse agonist activity linked to side effects, also prevented memory deficits in Fragile X mice.
Key Numbers
Rimonabant 0.01 mg/kg normalized cognition (30-300x below weight-loss doses). Rimonabant 0.1 mg/kg normalized mGluR-LTD brain signaling. Weight-loss doses in rodents: 3-10 mg/kg. NESS0327 (neutral antagonist) also effective for cognitive rescue.
How They Did This
Electrophysiological recordings measured mGluR-dependent long-term depression in brain slices from Fragile X knockout mice treated with low-dose rimonabant. Behavioral testing used the novel object recognition task to assess cognitive function. NESS0327 was tested as an alternative neutral antagonist.
Why This Research Matters
Fragile X syndrome has no approved pharmacological treatment. This study suggests that the endocannabinoid system is a viable therapeutic target and that the dose needed for treating cognitive deficits is far below the dose that caused problems in the obesity trials. This could potentially rehabilitate CB1 receptor targeting as a treatment strategy.
The Bigger Picture
The failure of rimonabant as an obesity drug due to psychiatric side effects was a major setback for cannabinoid receptor pharmacology. This study shows that not all therapeutic applications require the high doses that caused problems, potentially reopening a pathway for CB1-targeted medicines in neurological conditions.
What This Study Doesn't Tell Us
Mouse models of Fragile X syndrome do not fully replicate the human condition. The effective doses were for acute administration; long-term safety at low doses has not been established. Human pharmacokinetics may differ from mice. The neutral antagonist NESS0327 has limited preclinical data.
Questions This Raises
- ?Could very low-dose rimonabant or neutral CB1 antagonists be safely used in Fragile X patients?
- ?Would chronic low-dose treatment maintain efficacy without causing psychiatric side effects?
- ?Are there other genetic conditions where CB1 targeting might help?
Trust & Context
- Key Stat:
- Effective dose was 30-300x lower than the dose that caused psychiatric side effects
- Evidence Grade:
- Well-designed preclinical study with multiple outcome measures and a mechanistic alternative (neutral antagonist), but entirely in mice with uncertain clinical translation.
- Study Age:
- Published in 2016. Clinical translation of CB1-targeting approaches for Fragile X and other neurodevelopmental conditions remains an active area of research.
- Original Title:
- Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model.
- Published In:
- Genes, 7(9) (2016)
- Authors:
- Gomis-González, Maria(2), Busquets-Garcia, Arnau(8), Matute, Carlos(3), Maldonado, Rafael, Mato, Susana, Ozaita, Andrés
- Database ID:
- RTHC-01166
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
What is Fragile X syndrome?
The most common single-gene cause of intellectual disability, affecting about 1 in 4,000 boys and 1 in 8,000 girls. There is currently no approved drug treatment for the cognitive symptoms.
Why was rimonabant pulled from the market if it works here?
Rimonabant was an obesity drug that caused depression and anxiety at the high doses used for weight loss. This study shows that cognitive benefits in Fragile X mice occur at 30-300 times lower doses, potentially avoiding those side effects.
Read More on RethinkTHC
- THC-amygdala-anxiety-brain
- anandamide-weed-withdrawal
- cannabinoid-receptors-recovery-time
- cannabis-developing-brain-teenagers
- cant-enjoy-anything-without-weed
- dopamine-recovery-after-quitting-weed
- endocannabinoid-system-explained-simply
- endocannabinoid-system-withdrawal
- nervous-system-weed-withdrawal-fight-flight
- teen-weed-use-under-18-effects-brain
- thc-brain-withdrawal
- thc-prefrontal-cortex-brain-effects
- weed-cortisol-stress-hormones
- weed-memory-loss-recovery
- weed-motivation-amotivational-syndrome
- weed-nervous-system-effects
- weed-reward-system-brain
Cite This Study
https://rethinkthc.com/research/RTHC-01166APA
Gomis-González, Maria; Busquets-Garcia, Arnau; Matute, Carlos; Maldonado, Rafael; Mato, Susana; Ozaita, Andrés. (2016). Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model.. Genes, 7(9). https://doi.org/10.3390/genes7090056
MLA
Gomis-González, Maria, et al. "Possible Therapeutic Doses of Cannabinoid Type 1 Receptor Antagonist Reverses Key Alterations in Fragile X Syndrome Mouse Model.." Genes, 2016. https://doi.org/10.3390/genes7090056
RethinkTHC
RethinkTHC Research Database. "Possible Therapeutic Doses of Cannabinoid Type 1 Receptor An..." RTHC-01166. Retrieved from https://rethinkthc.com/research/gomis-gonzalez-2016-possible-therapeutic-doses-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.